Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.20 million
Profitability
Miscellaneous
Employees115
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics Inc (NASDAQ:JNCE) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.29. The business earned $20.10 million during the quarter, compared to the consensus estimate of $12.86 million. Jounce Therapeutics had a negative net margin of 41.99% and a negative return on equity of 25.69%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What price target have analysts set for JNCE?
6 brokerages have issued 1 year price targets for Jounce Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate Jounce Therapeutics' share price to reach $13.00 in the next year. This suggests a possible upside of 124.1% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.
What is the consensus analysts' recommendation for Jounce Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.
Has Jounce Therapeutics been receiving favorable news coverage?
Media stories about JNCE stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jounce Therapeutics earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Nightstar Therapeutics (NITE), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Heska (HSKA), DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR), Mesoblast (MESO), Krystal Biotech (KRYS), Avrobio (AVRO), Replimune Group (REPL), Scholar Rock (SRRK), PDL BioPharma (PDLI) and Adaptimmune Therapeutics (ADAP).
What other stocks do shareholders of Jounce Therapeutics own?
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 60)
- Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
- Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
- Dr. James P. Allison, Founder
- Dr. Thomas F. Gajewski, Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $5.80.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $191.24 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.
What is Jounce Therapeutics' official website?
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
